fda warning letters compounding semaglutide october 2025 Sends to More Than 50 GLP-1 Compounders and Manufacturers July 29, 2024: FDA issued

Societies recommend starting at age 40 if average risk, though I recommend a baseline at 35 yo as I practice in CT, which has the highest rate of early onset breast cancer in the U.S., said Kazanjian

How the weight loss drug tirzepatide is also helping heart failure patients Two clinical trials add evidence for the medication's benefits CHICAGO New clinical trial results on the diabetes and obesity drug tirzepatide have doctors buzzing about its potential to treat heart failure, keep weight off and prevent type 2 diabetes

less does the opposite

10.1111/j.1463-1326.2009.01075.x 62

27 In vitro activation of the GLP-1R by exendin-4 enhanced osteogenic differentiation while inhibiting adipogenic differentiation of BMSCs